16-70496367-C-T

Variant summary

Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PS1PM2PP3PP5_Very_Strong

The NM_015386.3(COG4):​c.1546G>A​(p.Gly516Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin Lovd.

Frequency

Genomes: not found (cov: 32)

Consequence

COG4
NM_015386.3 missense

Scores

6
4
7

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:7O:1

Conservation

PhyloP100: 7.71
Variant links:
Genes affected
COG4 (HGNC:18620): (component of oligomeric golgi complex 4) The protein encoded by this gene is a component of an oligomeric protein complex involved in the structure and function of the Golgi apparatus. Defects in this gene may be a cause of congenital disorder of glycosylation type IIj. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Aug 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 15 ACMG points.

PS1
Transcript NM_015386.3 (COG4) is affected with MISSENSE_VARIANT having same AA change as one Pathogenic present in Lovd
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.824
PP5
Variant 16-70496367-C-T is Pathogenic according to our data. Variant chr16-70496367-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 449730.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-70496367-C-T is described in Lovd as [Pathogenic]. Variant chr16-70496367-C-T is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
COG4NM_015386.3 linkuse as main transcriptc.1546G>A p.Gly516Arg missense_variant 12/19 ENST00000323786.10 NP_056201.2 Q9H9E3J3KNI1Q8N8L9
COG4NM_001195139.2 linkuse as main transcriptc.1534G>A p.Gly512Arg missense_variant 12/18 NP_001182068.2 Q9H9E3A0A0A0MS45Q8N8L9
COG4NM_001365426.1 linkuse as main transcriptc.1120G>A p.Gly374Arg missense_variant 13/20 NP_001352355.1
COG4NR_158212.1 linkuse as main transcriptn.1505G>A non_coding_transcript_exon_variant 12/19

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
COG4ENST00000323786.10 linkuse as main transcriptc.1546G>A p.Gly516Arg missense_variant 12/191 NM_015386.3 ENSP00000315775.5 J3KNI1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
32
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:7Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityMar 31, 2020- -
Pathogenic, criteria provided, single submitterclinical testingAthena DiagnosticsOct 08, 2020This variant appears to occur de novo in an individual tested at Athena Diagnostics and in multiple individuals with clinical features consistent with autosomal dominant Saul-Wilson syndrome (PMID 30290151). This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Computational tools yielded predictions that this amino acid change may be damaging to the protein.This observation is not an independent occurrence and has been identified in the same individual by RCIGM, the other laboratory participating in the GEMINI study. -
Pathogenic, criteria provided, single submitterclinical testingGeneDxNov 23, 2022Published functional studies demonstrate a significant increase in core proteins of HSPGs accumulation on the cell surface of G516R mutant cell lines and increased secretion of the SIL1 protein; findings which support a gain of function effect of the G516R variant (Sumya et al., 2021); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 34603392, 31949312, 30290151, 33688625, 34595172, 35455576, 36393834) -
Microcephalic osteodysplastic dysplasia, Saul-Wilson type Pathogenic:2Other:1
Pathogenic, no assertion criteria providedliterature onlyOMIMNov 29, 2018- -
Pathogenic, criteria provided, single submittercurationSIB Swiss Institute of BioinformaticsJul 11, 2019This variant is interpreted as a Pathogenic for Saul-Wilson syndrome, autosomal dominant. The following ACMG Tag(s) were applied: PM2; PS4-Moderate; PM6-Strong; PP3; PS3 -
not provided, no classification providedliterature onlyGeneReviews-- -
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsSep 17, 2021The c.1546G>A (p.G516R) alteration is located in exon 12 (coding exon 12) of the COG4 gene. This alteration results from a G to A substitution at nucleotide position 1546, causing the glycine (G) at amino acid position 516 to be replaced by an arginine (R). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). The p.G516R alteration has been reported as a recurrent de novo alteration in several patients with Saul-Wilson syndrome (Ferreira, 2018). This amino acid position is highly conserved in available vertebrate species. Fibroblasts from patients with the p.G516R alteration have been shown to have abnormal Golgi morphology and decreased Golgi volume compared to control samples. Glycan analysis and glycosylation status were not measurably different between patients and controls; however there was evidence of altered Golgi-dependent glycosylation and abnormal Golgi trafficking in patients (Ferreira, 2018) . The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. -
COG4-congenital disorder of glycosylation Pathogenic:1
Pathogenic, criteria provided, single submitterresearchUndiagnosed Diseases Network, NIHAug 23, 2017This individual has been reported in PMID: 30290151. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.22
D
BayesDel_noAF
Uncertain
0.080
CADD
Uncertain
25
DANN
Pathogenic
1.0
DEOGEN2
Benign
0.049
T;T
Eigen
Pathogenic
0.76
Eigen_PC
Pathogenic
0.79
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.97
D;D
M_CAP
Benign
0.047
D
MetaRNN
Pathogenic
0.82
D;D
MetaSVM
Benign
-0.66
T
PrimateAI
Pathogenic
0.86
D
PROVEAN
Benign
-1.7
N;.
REVEL
Uncertain
0.38
Sift
Benign
0.045
D;.
Sift4G
Benign
0.12
T;T
Vest4
0.91
MVP
0.68
MPC
0.70
ClinPred
0.98
D
GERP RS
6.0
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
gMVP
0.79

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs1555575860; hg19: chr16-70530270; COSMIC: COSV60421914; COSMIC: COSV60421914; API